{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:47:41Z","timestamp":1772826461927,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describe the characterization of a novel small molecule IDO1 inhibitor, NTRC 3883-0, in a panel of biochemical and cell-based assays, and various cancer models. NTRC 3883-0 released the inhibitory effect of IDO1 on CD8-positive T cell proliferation in co-cultures of IDO1-overexpressing cells with healthy donor lymphocytes, demonstrating its immune modulatory activity. In a syngeneic mouse model using IDO1-overexpressing B16F10 melanoma cells, NTRC 3883-0 effectively counteracted the IDO1-induced modulation of L-tryptophan and L-kynurenine levels, demonstrating its <jats:italic>in vivo<\/jats:italic> target modulation. Finally, we studied the expression and activity of IDO1 in primary cell cultures established from the malignant ascites of ovarian cancer patients. In these cultures, IDO1 expression was induced upon stimulation with IFN\u03b3, and its activity could be inhibited by NTRC 3883-0. Based on these results, we propose the use of ascites cell-based functional assays for future patient stratification. Our results are discussed in light of the recent discontinuation of clinical trials of more advanced IDO1 inhibitors and the reconsideration of IDO1 as a valid drug target.<\/jats:p>","DOI":"10.3389\/fimmu.2020.609490","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T14:06:44Z","timestamp":1611842804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0"],"prefix":"10.3389","volume":"11","author":[{"given":"Yvonne","family":"Grobben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"de Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoon M.","family":"van Doornmalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Willemsen-Seegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diep","family":"Vu-Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried R.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine B. W.","family":"Prinsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joeri","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Gerard","family":"Sterrenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freek","family":"van Cauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith E.","family":"den Ouden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"van Altena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon F.","family":"Massuger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost C. M.","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier C.","family":"Buijsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido J. R.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","article-title":"The therapeutic potential of targeting tryptophan catabolism in cancer","volume":"122","author":"Opitz","year":"2020","journal-title":"Br J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Th\u00e9ate","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(19)77982-4","article-title":"Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity","volume":"263","author":"Takikawa","year":"1988","journal-title":"J Biol Chem"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J Exp Med"},{"key":"B7","article-title":"Purification and properties of rat liver tryptophan oxygenase","volume":"247","author":"Schutz","year":"1972","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1087057114536616","article-title":"High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes","volume":"19","author":"Seegers","year":"2014","journal-title":"J Biomol Screen"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0061-3","article-title":"IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1","volume":"31","author":"Dill","year":"2018","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00942","article-title":"Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)","volume":"62","author":"R\u00f6hrig","year":"2019","journal-title":"J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I\/II Trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B18","article-title":"inventors; Netherlands Translational Research Center B.V., assignee. Inhibitors of indoleamine 2,3-dioxygenase","author":"De Man","year":"2017"},{"key":"B19","article-title":"inventors; Netherlands Translational Research Center B.V., assignee. Inhibitors of tryptophan 2,3-dioxygenase","author":"De Man","year":"2018"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ab.2005.10.039","article-title":"A fluorescence-based assay for indoleamine 2,3-dioxygenase","volume":"349","author":"Matin","year":"2006","journal-title":"Anal Biochem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16213","article-title":"Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines","volume":"8","author":"Libouban","year":"2017","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu127","article-title":"flowFit: a Bioconductor package to estimate proliferation in cell-tracking dye studies","volume":"30","author":"Rambaldi","year":"2014","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2219","DOI":"10.21769\/BioProtoc.2219","article-title":"Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites","volume":"7","author":"Wefers","year":"2017","journal-title":"BIO-PROTOCOL"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0213170","DOI":"10.1371\/journal.pone.0213170","article-title":"Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress","volume":"14","author":"Laing","year":"2019","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/173029","article-title":"Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation","volume":"2012","author":"Levina","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.07.015","article-title":"Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma","volume":"115","author":"Inaba","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3892\/or.17.6.1333","article-title":"Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer","volume":"17","author":"Takao","year":"2007","journal-title":"Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00950-1","article-title":"A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma","volume":"38","author":"Reardon","year":"2020","journal-title":"Invest New Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30312-2","article-title":"Echoes of a failure: what lessons can we learn","volume":"20","author":"Sondak","year":"2019","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 Inhibitors: From Bench to Bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2012.742037","article-title":"Persistent infectious diseases say - IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy","volume":"40","author":"Barth","year":"2014","journal-title":"Crit Rev Microbiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2011","article-title":"A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer","volume":"75","author":"D\u2019Amato","year":"2015","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2326-6066.CIR-19-0040","article-title":"Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers","volume":"8","author":"Hoffmann","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.358","article-title":"BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC)","volume":"37","author":"Luke","year":"2019","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0611","article-title":"ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with\/without linrodostat mesylate for muscle-invasive bladder cancer","volume":"16","author":"Sonpavde","year":"2020","journal-title":"Future Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.609490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T14:06:48Z","timestamp":1611842808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.609490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2020.609490"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.609490","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"article-number":"609490"}}